Bring RTSM In A Protocol Synopsis: Here's Why

Early conversations about a clinical trial often begin with only a protocol synopsis in hand — an outline of intentions rather than a fully defined operational plan. This clip explores why that early stage is a critical window for sponsors to tap into experienced partners who’ve seen similar studies play out hundreds of times.

The discussion highlights how teams familiar with a wide range of therapeutic areas, endpoints, and trial sizes can spot risks that aren’t yet visible in the synopsis. Some are IRT‑specific, such as likely amendment triggers or supply‑chain complexities. Others arise from logistics: how a kit will be prepared at the pharmacy, how it moves to the patient, and how timing requirements align with real site workflows.

Drawing on patterns across many protocols and study designs, these insights can surface operational blind spots long before the final protocol is locked. The clip shows how early, experience‑driven dialogue helps sponsors avoid predictable pitfalls and refine decisions while change is still easy — and far less costly.